Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Athenex.

Rapid Reviews in Oncology® from Chicago: Practice-Changing Data in Breast Cancer

Release Date: June 30, 2019
Expiration Date: September 25, 2020
Media: Internet - based

Activity Overview

This online activity is the enduring program from the Rapid Reviews in Oncology® legacy format, a live, in-studio video broadcast to rapidly update physicians on data that have been presented at the recent annual oncology meeting held in Chicago in June 2019. Chaired by renowned breast cancer expert and leading clinical researcher Joyce O’Shaughnessy, MD, the enduring broadcast consists of a panel discussion of groundbreaking data presented at the Chicago meeting. Dr. O’Shaughnessy and panelists Dr. Ruth O’Regan and Dr. Andrew D. Seidman present and comment on emerging data with the potential to change treatment for patients across the continuum of breast cancer. The expert panel highlights the implications and applications of these data for your practice, helping you optimize care for your patients with breast cancer.

Benefits of Participating

  • Stay up-to-date on the latest data pertaining to treatment and management of breast cancer across the spectrum of disease.
  • Benefit from expert analysis of the most recent data likely to impact clinical practice in breast cancer management in the near future.
  • Learn how experts in breast cancer research place emerging data into clinical context for the treatment and management of patients with breast cancer.

CME Activity Table of Contents

  • Pretest
  • Module 1: Welcome and Introduction
  • Module 2: Review of Comparative Abstracts: General Breast Cancer Therapy
  • Module 3: Review of Comparative Abstracts: ER+ Breast Cancer Therapy
  • Module 4: Review of Comparative Abstracts: HER2+ Breast Cancer Therapy
  • Module 5: Review of Comparative Abstracts: Triple-Negative Breast Cancer Therapy
  • Module 6: Audience Questions and Closing
  • Posttest and Evaluation

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Athenex.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, educational content/video files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with breast cancer. Surgical oncologists, radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Report recent evidence concerning novel treatment strategies from clinical trials conducted among patients with breast cancer
  • Assess the importance of ongoing and completed clinical trials informing the management of patients with breast cancer
  • Contextualize new evidence in the management of breast cancer in consideration of evolving treatment paradigms in the field

Faculty, Staff, and Planners’ Disclosures


Joyce O'Shaughnessy, MD
Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
Co-Chair, Breast Cancer Research Program
The US Oncology Network
Dallas, TX

Disclosures: Consultant/Advisory Board: Novartis, AstraZeneca, Lilly; Speakers Bureau: AstraZeneca, Lilly.


Ruth O'Regan, MD
Ruth O'Regan, MD
Professor, Department of Medicine
Chief, Hematology/Oncology & Palliative Medicine
University of Wisconsin Carbone Cancer Center
Madison, WI

Disclosures: Grant Research Support: Novartis, Pfizer, Eisai, Cascadian; Consultant: Novartis, Pfizer, Puma, Genentech, GHI, Biotheranostics, MacroGenics, Immunogenics.

Andrew D. Seidman, MD
Andrew D. Seidman, MD
Attending Physician, Breast Medicine Service
Medical Director, Bobst International Center
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Disclosures: Grant Research Support: Bayer, Odonate, Nektar; Consultant: Lilly, Novartis, Pfizer, Genentech, Eisai, Genomic Health; Speakers Bureau: Genomic Health, Genentech, Lilly, Novartis, AstraZeneca.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By